Teva's Seffalair And BroPair Spiromax Receive Approval In EU
EDGAR Filing Documents for 0001157523-13-004664
PDF) Assessment of inhalation errors, training time and patient preference for DuoResp® Spiromax® and Symbicort® Turbuhaler® in patients with asthma and COPD
Teva recibe la autorización de comercialización en la UE para Seffalair Spiromax y BroPair Spiromax para el tratamiento del asma
Spiromax device. Copyright of Teva UK Limited. Reproduced with permission. | Download Scientific Diagram
DuoResp Spiromax | Healthify
Formoterol | Teva UK
Teva's DuoResp Spiromax Wins Medical Design Excellence Award | RT
EU Authorizes Teva's Seffalair® Spiromax® and BroPair® Spiromax®
Teva receives EU Marketing Authorisation for Seffalair® Spiromax® and BroPair® Spiromax® (salmeterol xinafoate / fluticasone propionate) | Business Wire
Duoresp Spiromax (Teva) | Bioz | Ratings For Life-Science Research